Tagged: non-small cell lung cancer

Figure 2: Overview of brigatinib’s and alectinib’s mechanisms of action. Receptor targets of each drug are depicted through the cell membrane and the following pathways and pathophysiological motives affected are depicted from the cell surface to the nucleus. Alectinib acts through ALK and RET, involved mainly in survival and proliferation, while brigatinib acts also through ALK and FLT3, IGF1R, and EGFR, signaling through overlapping intracellular mechanisms affecting cell survival and proliferation, metastasis, apoptosis and migration. Bibliographical validation information of interactions on the predicted mechanisms of action are shown in Supplementary data (Supplementary Table 1).

Trending with Impact: Machine Learning Used to Compare ALK Inhibitors

Researchers use a computer simulated modeling system to highlight the strengths and weaknesses of two... read more

March 4, 2021

Photomicrograph of fine needle aspiration (FNA) cytology of a pulmonary (lung) nodule showing adenocarcinoma, a type of non small cell carcinoma.

Trending with Impact: Novel MicroRNA Underexpressed in Lung Cancer

In search of new ways to target lung cancer cells, researchers in this study demonstrated... read more

February 4, 2021